Benutzer: Gast  Login
Titel:

A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).

Dokumenttyp:
Journal Article; Clinical Trial; Clinical Trial, Phase I; Article
Autor(en):
Meyer, RG; Britten, CM; Siepmann, U; Petzold, B; Sagban, TA; Lehr, HA; Weigle, B; Schmitz, M; Mateo, L; Schmidt, B; Bernhard, H; Jakob, T; Hein, R; Schuler, G; Schuler-Thurner, B; Wagner, SN; Drexler, I; Sutter, G; Arndtz, N; Chaplin, P; Metz, J; Enk, A; Huber, C; Wölfel, T
Abstract:
A significant percentage of patients with stage II melanomas suffer a relapse after surgery and therefore need the development of adjuvant therapies. In the study reported here, safety and immunological response were analyzed after vaccination in an adjuvant setting with recombinant modified vaccinia virus Ankara carrying the cDNA for human tyrosinase (MVA-hTyr). A total of 20 patients were included and vaccinated three times at 4-week intervals with 5x10(8) IU of MVA-hTyr each time. The respons...     »
Zeitschriftentitel:
Cancer Immunol Immunother
Jahr:
2005
Band / Volume:
54
Heft / Issue:
5
Seitenangaben Beitrag:
453-67
Sprache:
eng
Volltext / DOI:
doi:10.1007/s00262-004-0616-7
PubMed:
http://view.ncbi.nlm.nih.gov/pubmed/15627214
Print-ISSN:
0340-7004
TUM Einrichtung:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie); Institut für Virologie ; Klinik und Poliklinik für Dermatologie und Allergologie
 BibTeX